Adherence to Otezla

• Status: Not yet recruiting
• Trial end date: 2024-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Most people with psoriasis have very limited disease, yet that disease may still have a large impact on their lives. While limited psoriasis may be amenable to topical treatment, patients are exceptionally poorly adherent to topical treatment, especially over the long run.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wake Forest University Health Sciences
• Collaborator: Amgen
• Treatments: Apremilast; Thalidomide

Criteria

Inclusion Criteria:

• Adult 18 years or older

• Diagnosis of mild psoriasis with Otezla recommendation

• Non-pregnant

• English speaking

Exclusion Criteria:

• Under 18 years of age

• Not diagnosis of mild psoriasis

• Pregnant

• Non-English speaking